These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21990398)

  • 1. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.
    Del Vecchio M; Mortarini R; Tragni G; Di Guardo L; Bersani I; Di Tolla G; Agustoni F; Colonna V; Weber JS; Anichini A
    J Clin Oncol; 2011 Nov; 29(32):e783-8. PubMed ID: 21990398
    [No Abstract]   [Full Text] [Related]  

  • 2. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab: showing survival benefit in metastatic melanoma.
    Minchom A; Young K; Larkin J
    Future Oncol; 2011 Nov; 7(11):1255-64. PubMed ID: 22044200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
    Pennock GK; Waterfield W; Wolchok JD
    Am J Clin Oncol; 2012 Dec; 35(6):606-11. PubMed ID: 21336089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
    Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
    JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
    Robert C; Ghiringhelli F
    Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report.
    Loquai C; Müller-Brenne T; Schadmand-Fischer S; Grabbe S
    Onkologie; 2013; 36(10):578-81. PubMed ID: 24107912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab. Immunostimulant; more assessment needed.
    Prescrire Int; 2012 Jun; 21(128):145-7. PubMed ID: 22822590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
    Bakacs T; Mehrishi JN; Szabó M; Moss RW
    Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological immune-related adverse events of ipilimumab.
    Bot I; Blank CU; Boogerd W; Brandsma D
    Pract Neurol; 2013 Aug; 13(4):278-80. PubMed ID: 23487828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.